Sarepta Therapeutics Inc. (NASDAQ:SRPT) was up 6.7% during mid-day trading on Wednesday . The stock traded as high as $28.80 and last traded at $28.00, with a volume of 2,387,515 shares traded. The stock had previously closed at $26.24.

Several equities research analysts have issued reports on SRPT shares. WBB Securities restated a “buy” rating and set a $40.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, April 26th. Robert W. Baird restated a “buy” rating on shares of Sarepta Therapeutics in a research report on Sunday, May 8th. Vetr upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $17.28 price objective for the company in a research report on Thursday, May 12th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Finally, Needham & Company LLC raised their target price on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, July 22nd. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $25.28.

The firm’s market cap is $1.30 billion. The company has a 50-day moving average price of $23.96 and a 200 day moving average price of $19.05.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm posted ($0.87) EPS. Equities research analysts forecast that Sarepta Therapeutics Inc. will post ($5.16) EPS for the current year.

A hedge fund recently raised its stake in Sarepta Therapeutics stock. Jennison Associates LLC raised its position in shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) by 463.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 838,629 shares of the company’s stock after buying an additional 689,831 shares during the period. Jennison Associates LLC owned approximately 1.85% of Sarepta Therapeutics worth $32,354,000 as of its most recent filing with the SEC.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.